Symposium - 2021
2021 Virtual Immuno-Oncology Symposium
On Tuesday, February 9, 2021, The Centre for Translational Cancer Research hosted the 2nd Annual Immuno-Oncology Symposium with 450 registrants from 19 different countries and over 130 different institutions. The day ran from 9am to 15:30pm EST. The event was hosted virtually from London, Ontario, Canada.
Guest Speakers Included:
Lisa Butterfield, PhD. - Vice President, PICI Research and Development, Parker Institute for Cancer Immunotherapy. Adjunct Professor, Department of Microbiology and Immunology, University of California San Francisco.
*Research focuses on cancer vaccines and cellular therapies for melanoma, hepatocellular cancer and other tumor types.
Vinod P. Balachandran, MD. - Surgical Oncologist, Memorial Sloan Kettering Cancer Center. Member, David M. Rubenstein Center for Pancreatic Cancer Research and Parker Institute for Cancer Immunotherpy.
*Research focuses on understanding T-cell immunobiology in cancer and to facilitiate development of novel cancer vaccines and immunotherapies.
Timothy Chan, MD. PhD. - Director, Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic. Radiation Oncologist, Genomic Medicine Institute and the Taussig Cancer Institute.
*Research focuses on precision immuno-oncology and using genomics to determine which patients will respond best to certain types of immunotherapies.
Max Diehn, MD. PhD. - CRK Faculty Scholar and Associate Professor, Department of Radiation Oncology, Stanford Medicine. Vice Chair, Research & Division of Radiation and Cancer Biology. Stanford Cancer Institute and Institute for Stem Cell Biology & Renegerative Medicine.
*Research focuses on developing a better understanding of the initiation, maintenance, progression, and treatment response of carcinomas. Specific areas of focus inlcude cancers of the lung, breast, and gastrointestinal system.
Bernard A. Fox, PhD. - Chief, Laboratory of Molecular and Tumor Immunology. Harder Family Chair for Cancer Research. Robert W. Franz Cancer Research Center. Earle A. Chiles Research Institute. Providence Cancer Center
*Research focuses on translating combination immunotherapy findings from preclinical models to patients with advanced cancer. Strategy includes a prime/boost with complex cancer vaccines, T cell agonists and delayed anti-PD-1.
Jennifer McQuade, MD. MS. MA. LAc. - Assistant Professor, Department of Melanoma Medical Oncology, University of Texas. Physician Scientist in Melanoma Medical Oncology, MD Anderson Cancer Center.
*Research focuses on how lifestyle factors incluence melanoma biology and the anti-tumor immune response with the goal of developing novel strategies to improve outcomes in melanoma.
Agenda
Conference Chair: Saman Maleki, PhD.
8:45 - 9:00 Zoom Sign In
9:00 - 9:15 Welcome and Opening Remarks
Saman Maleki, PhD. - Conference Chair
John Yoo, MD - Dean, Schulich School of Medicine & Dentistry, Western University
Glenn Bauman, MD. FRCPC. - Director, Centre for Translational Cancer Research
9:15 - 10:00 Timothy Chan, MD. PhD. - "How T Cells recognize Tumor Cells"
10:00 - 10:20 Kim Chan, PhD. - "Bispecific T-cell Engager (BiTE®) Immune Therapy for Cancer"
10:20 - 10:30 Health Break
10:30 - 11:15 Vinod P. Balachandran, MD. - “Pancreatic cancer: from long-term survivors to new immunotherapies”.
11:15 - 12:00 Jennifer L. McQuade, MD. MS. MA. LAc. - "The Microbiome, Diet, and Immune Response: From Observation to Intervention".
12:00 - 12:20 Melanie Spears, PhD. - "Molecular profiling to assess the immune response to neoadjuvant SABR in early breast cancer".
12:20 - 12:45 Lunch Break & Zoom Sign-In
12:45 - 13:30 Lisa H. Butterfield, PhD. - "Cancer Vaccination & Immune Profiling in Cancer Patients".
13:30 - 13:50 Ian Wilson, PhD. - "Imaging of CD8 T cells; Clinical Development of Immuno-PET Tracer 89Zr IAB22M2C".
13:50 - 14:00 Health Break
14:00 - 14:45 Bernard A. Fox, PhD. - "Triplet Immunotherapy for Head and Neck Cancer: Complex Vaccines, T cell Agonists, and Checkpoint Blockade".
14:45 - 15:30 Max Diehn, MD. PhD. - "Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition."
15:30 Closing Remarks
Saman Maleki, PhD.
